Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Chi-Med Granted US Fast Track Designation for Surufatinib in Pancreatic Neuroendocrine Tumors

publication date: Apr 17, 2020

Hutchison China MediTech (Chi-Med) reported the US FDA has granted Fast Track Designations to surufatinib as a treatment for two pancreatic neuroendocrine tumor (NET) indications. The indications are for advanced and progressive pancreatic NET and extra-pancreatic (non-pancreatic) NET in patients who are not amenable for surgery. In January, a China Phase III trial of surufatinib in NET was stopped early when data showed the candidate met its primary endpoint in an interim analysis. Surufatinib is an oral drug that inhibits angiogenesis and promotes a patient's immune response. More details....

Stock Symbols: (NSDQ/AIM: HCM)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.